Literature DB >> 2296812

Single-stage transrectal transsphincteric (modified York-Mason) repair of rectourinary fistulas.

T W Wood1, R G Middleton.   

Abstract

Over the past eleven years we have repaired seven rectourinary fistulas using a modified York-Mason transrectal transsphincteric approach. The simplicity of this one-stage procedure has demonstrated its cost effectiveness compared with the standard three-stage procedure (colostomy and cystotomy, fistula repair, and colostomy takedown).

Entities:  

Mesh：

Year:  1990        PMID： 2296812     DOI： 10.1016/0090-4295(90)80007-a

Source DB:  PubMed          Journal:  Urology        ISSN： 0090-4295            Impact factor:   2.649


  6 in total

1.  Considerations before repair of acquired rectourethral and urethrovaginal fistulas in children.

Authors:  Guo-Chang Liu; Hui-Min Xia; Ying-Quan Wen; Li-Yu Zhang; Zhong-Min Li
Journal:  World J Pediatr       Date:  2008-02       Impact factor: 2.764

2.  York Mason procedure to repair iatrogenic rectourinary fistula: our experience.

Authors:  Cristina Falavolti; Federico Sergi; Ervin Shehu; Maurizio Buscarini
Journal:  World J Surg       Date:  2013-12       Impact factor: 3.352

3.  [Fistula surgery].

Authors:  C M Rosenbaum; M W Vetterlein; M Fisch
Journal:  Urologe A       Date:  2020-04       Impact factor: 0.639

4.  Surgical Treatment of Iatrogenic Rectourinary Fistula-York-Mason Technique-a Case Report.

Authors:  Pedro Bargão Santos; Fernando Ferrito; Rocha Pires
Journal:  ISRN Urol       Date:  2011-06-15

5.  Treatment of a recurrent rectourethral fistula by using transanal rectal flap advancement and fibrin glue: a case report.

Authors:  Taek-Gu Lee; Sung-Su Park; Sang-Jeon Lee
Journal:  J Korean Soc Coloproctol       Date:  2012-06-30

6.  Urorectal fistula repair using different approaches: operative results and quality of life issues.

Authors:  Javier C Angulo; Ignacio Arance; Yannick Apesteguy; João Felicio; Natália Martins; Francisco E Martins
Journal:  Int Braz J Urol       Date:  2021 Mar-Apr       Impact factor: 1.541
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.